Dr Sonja Gill (Heidorn)
Position: Discovery Safety Specialist (DNA damage response and combinations)
Personal home page:
PubMed journal articles - click here
Safety assessment of oncology drugs (and combinations) with particular focus on the bone marrow.
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma http://www.ncbi.nlm.nih.gov/pubmed/26505995 Systematic identification of genomic markers of drug sensitivity in cancer cells. http://www.ncbi.nlm.nih.gov/pubmed/22460902 Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. http://www.ncbi.nlm.nih.gov/pubmed/20141835